Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison -
3 hours ago
- #first-line therapy
- #EGFR-mutated NSCLC
- #indirect treatment comparison
- Indirect comparison study of osimertinib (Osi) monotherapy vs. Osi plus platinum-based chemotherapy (Osi+CT) vs. amivantamab plus lazertinib (Ami+Laz) in first-line metastatic EGFR-mutated NSCLC.
- No statistically significant difference in progression-free survival (PFS) between Osi+CT and Ami+Laz (HR 0.79, 95% CI 0.61-1.04), with numerically longer PFS-RMST at 30 months for Osi+CT (22.53 vs. 20.59 months).
- No statistically significant overall survival (OS) differences observed between regimens (HR 0.95, 95% CI 0.73-1.22).
- Subgroup analyses for CNS metastases and EGFR mutation subtypes showed no conclusive PFS differences.
- Safety profiles differed: Osi+CT had higher grade ≥3 hematologic/gastrointestinal toxicities, while Ami+Laz had higher dermatologic events, infusion reactions, hypoalbuminemia, and peripheral edema.
- Study concludes comparable survival benefits between Osi+CT and Ami+Laz, with toxicity profiles influencing treatment decisions based on patient characteristics and preferences.